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Abstract
Background—Mutation in the progranulin gene (GRN) can cause frontotemporal dementia
(FTD). However, it is unclear whether some rare FTD-related GRN variants are pathogenic and
whether neurodegenerative disorders other than FTD can also be caused by GRN mutations.
Objectives—To delineate the range of clinical presentations associated with GRN mutations and
to define pathogenic candidacy of rare GRN variants.
Design—Case-control study.
Setting—Clinical and neuropathology dementia research studies at 8 academic centers.
Participants—Four hundred thirty-four patients with FTD, including primary progressive
aphasia, semantic dementia, FTD/amyotrophic lateral sclerosis (ALS), FTD/motor neuron disease,
corticobasal syndrome/corticobasal degeneration, progressive supranuclear palsy, Pick disease,
dementia lacking distinctive histopathology, and pathologically confirmed cases of frontotemporal
lobar degeneration with ubiquitin-positive inclusions (FTLD-U); and 111 non-FTD cases
(controls) in which TDP-43 deposits were a prominent neuropathological feature, including
subjects with ALS, Guam ALS and/or parkinsonism dementia complex, Guam dementia,
Alzheimer disease, multiple system atrophy, and argyrophilic grain disease.
Main Outcome Measures—Variants detected on sequencing of all 13 GRN exons and at least
80 base pairs of flanking introns, and their pathogenic candidacy determined by in silico and ex
vivo splicing assays.
Results—We identified 58 genetic variants that included 26 previously unknown changes.
Twenty-four variants appeared to be pathogenic, including 8 novel mutations. The frequency of
GRN mutations was 6.9% (30 of 434) of all FTD-spectrum cases, 21.4% (9 of 42) of cases with a
pathological diagnosis of FTLD-U, 16.0% (28 of 175) of FTD-spectrum cases with a family
history of a similar neurodegenerative disease, and 56.2% (9 of 16) of cases of FTLD-U with a
family history.
Conclusions—Pathogenic mutations were found only in FTD-spectrum cases and not in other
related neurodegenerative diseases. Haploinsufficiency of GRN is the predominant mechanism
leading to FTD.
FRONTOTEMPORAL DEMENTIA (FTD) is a heterogeneous group of diseases that present with language
and/or behavioral problems frequently in association with a movement disorder. It consists
of a spectrum of clinical and pathological diagnoses that includes corticobasal degeneration,
FTD with amyotrophic lateral sclerosis (FTD/ALS) or motor neuron disease, progressive
supranuclear palsy, Pick disease, and dementia lacking distinctive histopathology.
Frontotemporal dementia is familial in 25% to 50% of cases and can occur as an autosomal
dominantly inherited disorder with high penetrance.1-5 Genes causing this type of FTD
include MAPT, the gene encoding tau, CHMP2B, and GRN, the gene that encodes
progranulin (PGRN). In other families, autosomal dominant FTD is caused by as yet
unidentified genes located at 9p12-p216,7 and 9q21-q11.8 In MAPT mutation cases, the
predominant autopsy feature is aggregated tau as neurofibrillary and, in some cases, glial
tangles. In GRN mutation cases, the predominant deposited protein is ubiquitinated TAR
DNA binding protein (TARDBP or TDP-43), and tau tangles are rarely seen. Most of the
known GRN mutations are either nonsense mutations that result in a premature stop codon
or splicing mutations that alter the reading frame of the messenger RNA (mRNA), resulting
in a premature stop codon downstream from the mutation.9-12 The result is that the mutant
mRNA is degraded by nonsense-mediated decay (NMD), no protein is produced from the
mutant gene, and FTD is caused by haploinsufficiency of PGRN. A single missense
mutation (p.A9D) that is clearly pathogenic is known.11,13 This mutation is located within
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the signal peptide sequence and leads to cytoplasmic missorting, low PGRN levels, and
haploinsufficiency. Mutations in the TARDBP gene can cause either ALS or FTD.
In this study, we screened a large number of subjects with FTD-related neurodegenerative
disorders for mutations in GRN. The goal was 2-fold. First, we wanted to further delineate
the range of clinical presentations associated with GRN mutations. The initial studies of
GRN were on subjects with FTD, all of whom had TDP-43 deposits. Subsequent work
showed that TDP-43 inclusions are also found in idiopathic ALS,14 frontotemporal dementia
with inclusion body myopathy,15 Guam ALS/parkinsonism dementia complex,16 and some
cases of Alzheimer disease (AD).17 Therefore, additional cases were included in this study
to encompass a broad range of clinical phenotypes including a subset of non-FTD cases,
some of which have been associated with TDP-43 pathological features. Second, we sought
to evaluate the pathogenicity and potential molecular mechanism of rare GRN variants
associated with the disease. We observed 8 new GRN mutations that are clearly pathogenic,
including nonsense mutations, deletions, or splice-site mutations that generate premature
stop codons. One large (193 base pair [bp]) deletion observed previously by others18 had
unusual neuropathological findings including abnormal tau deposits. In addition, we
observed other variants that may be pathogenic, including a silent mutation that potentially
alters splicing and a missense variant that alters a critical amino acid that is part of the
conserved consensus sequence for granulin peptides. Our findings show that pathogenic
GRN mutations are only found in FTD-spectrum cases and that haploinsufficiency is their
predominant mechanism leading to FTD.
METHODS
STUDY SAMPLES FOR GRN MUTATION SCREENING AND CONTROLS
We screened 545 cases from the clinical and neuropathology dementia research studies at
the University of Washington, University of Pennsylvania, University of California at San
Diego, University of California at San Francisco, University of Southern California, Oregon
Health & Science University, University of British Columbia in Vancouver, and Center for
Neuropathology and Prion Research in Munich, Germany (Table 1). We selected cases on
the basis of having a clinical or autopsy-confirmed diagnosis of FTD and FTD-related
disorders. Cases of FTD with known MAPT mutations and cases of ALS with known SOD1
mutations were excluded. Control samples were from neurologically healthy control
participants, who were of a similar age and ethnic origin, from the University of California
at San Diego and Veterans Affairs Medical Center, San Diego; the Coriell Institute,
Camden, NJ (neurologically normal white control panels); clinical controls from the
Alzheimer Disease Center at the University of Pennsylvania; and brain autopsy samples
without evidence of neurodegenerative diseases from the University of Pennsylvania. All
subjects were studied with institutional review board approval for human subjects from each
institution.
DNA SEQUENCING AND GENOTYPING
The 13 exons of GRN (GenBank NM_002087.2) and at least 80 bp of their flanking introns
were fully sequenced in both directions. These fragments were polymerase chain reaction
(PCR) amplified from genomic DNA by means of primers that were selected by Primer3
software19; primer sequences were reported in previous publications from our group.20,21
The PCR was carried out by mixing 20 pmol of primers and 20 ng of genomic DNA with 10
μL of DNA PCR master mix (HotStarTaq; Qiagen, Valencia, California) in a final volume
of 20 μL. After 32 cycles, 2 μL of a PCR cleanup reagent (ExoSAP-IT; USB, Cleveland,
Ohio) was added to the PCR products and digested for 1 hour at 37°C to remove the residual
primers and deoxyribonucleotide triphosphates. Four microliters of the reagent-treated PCR
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fragments was sequenced with a terminator cycle sequencing kit (BigDye; Applied
Biosystems Inc, Foster City, California) in a final volume of 10 μL and 25 cycles. The
sequence information was collected and analyzed (3100 Genetic Analyzer; Applied
Biosystems), and nucleotide variants were identified by sequence alignment using
SEQUENCHER software (Gene Codes Corp, Ann Arbor, Michigan) or Mutation Surveyor
(Soft Genetics LLC, State College, Pennsylvania). Genetic variants were designated in both
DNA and protein levels according to the nomenclature guidelines of the Human Genome
Variation Society (http://www.hgvs.org/mutnomen). For genotyping, allele discrimination
assays were custom made (TaqMan; Applied Biosystems) and genotyped in 384 control
individuals. Genotyping was performed on 384-well plates with 5 ng of genomic DNA,
0.075 μL of 20× single-nucleotide polymorphism genotyping assay (TaqMan), 1.5 μL of
PCR assay mix (TaqMan Universal PCR Master Mix), and 1.425 μL of distilled water in
each well. The PCR was carried out with an amplification system (GeneAmp PCR System
9700, Applied Biosystems) with a profile of 95°C for 10 minutes and then 50 cycles at 92°C
for 15 seconds and 60°C for 90 seconds. Plates were then subjected to end-point read in a
real-time quantitative PCR system (7900 Real-Time PCR System, Applied Biosystems). The
results were first evaluated by cluster variations; the allele calls were then assigned
automatically before being transferred and integrated into the genotype database.
We defined polymorphism as “a change found at a frequency of 1% or higher in the
controls.”22 Minor allele frequencies of the variants were generated either by genotyping in
our 760 control chromosomes or by combining the genotyping results of previously
published references (Table 2). A selected number of mutations were evaluated in an
additional series of 732 control chromosomes as indicated in Table 2.
EX VIVO SPLICING ASSAYS
Heterologous constructs contained a single GRN exon and its flanking 100-bp intronic
sequences, inserted between heterologous exons. Both alleles of the target locus were PCR
amplified from a heterozygous subject’s genomic DNA by means of primers that were
integrated with restriction enzyme sites on their 5′ end. The PCR-amplified fragments were
double-digested with restriction enzymes XhoI and BamHI and inserted into the same
double-digested expression vector pSPES.33 Multiple clones were isolated and fully
sequenced to select for clones representing both alleles of the variation without additional
PCR artifacts. Minigene constructs contained 3 exons and their 2 internal introns with the
target exon located in the middle, representing the actual exon-intron setting of the original
gene structure. The same cloning procedure for heterologous construct was followed except
that the vector pRc/RSV (Invitrogen, Carlsbad, California) and restriction enzyme sites of
HindIII and XbaI were used in the minigene constructs. These constructs were then
transiently transfected into a rat pheochromocytoma cell line (PC12). PC12 cells were
cultured in Dulbecco modified Eagle medium supplemented with 5% fetal bovine serum,
10% horse serum, and penicillin (100 units/mL)/streptomycin (100 μg/mL) and seeded in
triplicate 25-cm2 flasks to achieve 50% to 70% confluency 1 day before transfection. PC12
cells were transfected with 5 μg of plasmid DNA and 60 μL of a transfection reagent
(Lipofectamine; Invitrogen) in 1.5 mL of medium (Opti-MEM; Invitrogen) for 4 hours at
37°C (5% carbon dioxide), after which 1.5 mL of Dulbecco modified Eagle medium
supplemented with 20% horse serum and 10% fetal bovine serum was added. Transfected
PC12 cells were harvested 24 hours after transfection. Total RNA was isolated (RNAeasy;
Qiagen). Transcripts from transiently transfected splicing vectors were analyzed by reverse-
transcription PCR assays by means of either SD6/SA2 primer pairs (for heterologous
constructs) or GRN exon primers (for minigene constructs). Amplified reverse-transcription
PCR products were resolved on agarose gel electrophoresis and visualized with ethidium
bromide staining. These products were excised and extracted from the gel (GFX Gel Band
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Purification Kit; GE Healthcare, Piscataway, New Jersey) and then subjected to DNA
sequencing to determine their nucleotide content. Primer sequences of constructs and PCR
conditions will be provided on request.
RESULTS
STUDY SUBJECT
We screened GRN for mutations in a spectrum of patients with FTD (n=434) that included
some subjects with primary progressive aphasia, semantic dementia, FTD/ALS, FTD with
motor neuron disease, corticobasal syndrome (CBS)/corticobasal degeneration, progressive
supranuclear palsy, Pick disease, dementia lacking distinctive histopathology, and
pathologically confirmed cases of frontotemporal lobar degeneration with ubiquitin-positive
inclusion (FTLD-U) (Table 1). Cases known to have mutations in MAPT, APP, PSEN1,or
PSEN2 were excluded; however, not all cases were screened for mutations in these genes. In
our cohort, 55.2% (175 of 317) of the patients with FTD for whom information was
available had a definite or possible family history of a similar neurodegenerative disease. To
date, all patients with GRN mutations evaluated pathologically had TDP-43 deposits.
Therefore, we also screened non-FTD cases in which TDP-43 deposits were a prominent
neuropathological feature. These cases included subjects with ALS, Guam ALS and/or
parkinsonism dementia complex, Guam dementia, AD, multiple system atrophy, and
argyrophilic grain disease (Table 1). All GRN exons, along with at least 80 bp of the
flanking introns, were sequenced.
GRN VARIANTS
We observed 58 different genetic variants, of which 46 (79.3%) were single-nucleotide
substitutions and 12 were insertion-deletions (indel) (Table 2 and eTable 1
[http:///www.archneurol.com]). Of these, 26 are novel variants not previously described.*
We considered a variant as potentially pathogenic if it was not observed in controls and if
the variant was in the coding region of the gene. Thus, the 8 variants found in controls and 3
in the 3′ untranslated region were not considered in the subsequent analysis. Of the 434 FTD
cases screened, 41 (9.4%) had a rare variant not observed in controls.
FRAMESHIFT PATHOGENIC MUTATIONS
We observed 22 mutations that resulted in a premature stop codon and were thus considered
pathogenic. Eight were nonsense mutations, including 1 not previously observed (p.S116X).
We also found 8 small indels in coding sequences that caused frameshifts resulting in
premature stop codons. Four of these are novel and are predicted to produce truncated
proteins that are missing the 148, 297, 306, and 337 C-terminal amino acids of PGRN
(Table 2). We also found a large deletion (c.1414- 16_1590del), which is described in more
detail in the next paragraph. We identified 5 variants (3 of which are novel) in either the 5′
splice site or the 3′ splice site of GRN exons (Table 2 and eTable 2). All are within 2 bp of
the exon-intron junctions and alter the consensus sequence for splice sites. All are predicted
by in silico methods39 to reduce use of the affected splice site, cause exon skipping, and
generate a downstream premature stop codon. We used ex vivo splicing assays to test these
predictions, and all 5 mutations showed altered splicing. Four of the mutations completely
inactivated the splice site, and the exon was completely excluded from the resulting
transcript. The remaining mutation (c.1414-2A>G) resulted in only a partial reduction in use
of the affected splice site. The proband for the c.1414-2A>G mutation, subject UP52a, had 2
affected siblings (neither of whom were available for testing). However, 1 of these siblings
*References 9-12, 18, 20, 21, 23-26, 29-32, 34-38.
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was an obligate carrier because this person had a child who carried the same variant and
who was affected with semantic dementia with onset at 52 years of age. Thus, the splicing
data and cosegregation of this mutation support the conclusion that this splice site change is
pathogenic. Gel image of splicing assays will be provided on request.
We observed a large deletion (c.1414-16_1590del) that removed 193 bp, starting in intron
10 (I10) and extending 177 bp into exon 11 (E11). The effect of this mutation on mRNA
splicing was tested in ex vivo splicing experiments with the use of a minigene that contained
the E10-I10-E11-I11-E12 segment of GRN. Constructs were generated that had sequences
either from the normal or from the deletion allele. Splicing of the normal allele removed I10
and I11, leaving E10-E11-E12 correctly spliced. The deletion allele produced 2 products, 1
of which was unspliced with both I10 and I11 retained, and a second product with I10
retained and I11 removed. In vivo, both products would cause a frameshift and a predicted
protein truncated at amino acid 481, resulting in haploin-sufficiency. Clinically, this patient
(ARC62) had a “left alien hand” and a diagnosis of CBS. The neuropathological findings in
this case are somewhat atypical for a GRN mutation. Cortical atrophy was most severe in
frontal and temporal lobes but extended to include the parietal lobes. Basal cerebral
structures appeared normal, although the substantia nigra was pale. Hematoxylin-eosin–
stained sections of all cerebral lobes showed dramatic cortical neuron loss, vacuolization,
and intense gliosis with marked degeneration of underlying white matter and gliosis that was
worst in the frontal lobes (Figure 1). Similarly prominent neuron loss and gliosis also were
present in the globus pallidus and substantia nigra. The hippocampus was spared. Tau
immunoreactivity (IR) in cerebral cortical sections showed scattered small rounded or
curved cytoplasmic neuronal inclusions but not neurofibrillary tangles, as well as abundant
glial tau IR that in several instances appeared as “tufted” astrocytes. More numerous tau IR
deposits were present in the underlying cortical white matter. Ubiquitin- and TDP-43–IR
neuronal cytoplasmic inclusions were identified in affected regions of cerebral cortex and in
the granule neurons of the hippocampus. Ubiquitin, but not TDP-43, IR inclusions and
deposits were numerous in affected cerebral white matter. This same mutation was reported
in an FTD case with ubiquitin-positive inclusions.18
MISSENSE VARIANTS
We identified 16 missense changes, of which 8 are novel (Table 2, eTable 1, and eTable 3).
Of these, 8 were considered potentially pathogenic because they did not appear in controls
(p.A9D, p.V77I, p.C105R, p.T182M, p.T251S, p.A276V, p.R298H, and p.P357R). The
p.A9D variant is clearly pathogenic because it cosegregates with disease in a large FTD
kindred.34 We performed in silico analysis using the PMut,40 PolyPhen,41 and SIFT42
programs to predict whether the variants potentially altered protein function. Among the 16
missense variants, one, p.R212W, was predicted by all 3 algorithms to alter protein function
(eTable 3). Another 6 variants (p.A9D, p.R19W, p.G70S, p.C105R, p.T182M, and
p.R433W) were predicted to be deleterious by 2 algorithms. The C105R change alters a
conserved cysteine that is part of the consensus sequence that defines granulin peptides.
Thus, p.C105R potentially alters granulin peptide function after secretion, a mechanism not
previously implicated in GRN mutation pathogenesis. Eight other missense mutations also
fall within the granulin peptide sequences (eTable 3).
Missense variants could also be pathogenic by altering exon-splicing enhancers (ESEs) or
exon-splicing silencers, thereby causing exon skipping and downstream premature stop
codons. We tested 7 candidate missense variants in ex vivo splicing assays and found that
A276V altered splicing. Variant A276V (c.827C>T) showed an altered splicing pattern in
the heterologous construct experiment, but this splicing alteration was not observed in the
minigene construct. Because it was not observed in the controls, A276V is a potential
pathogenic mutation.
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SILENT VARIATIONS
We identified 4 silent changes in coding exons of GRN and one of these, c.159G>A (p.L53),
was not present in controls. These changes, like the missense mutations described in the
previous section, have the potential to alter splicing. We analyzed the variant sequences in
silico for potential effects on ESEs by means of the RESCUE-ESE algorithm43 (eTable 4).
We also tested these variants in ex vivo splicing assays. The in silico analysis predicted that
the rare alleles of c.99C>T (E1) and c.159G>A (E2) would add ESE sites that could enhance
exon inclusion. However, these variants did not affect splicing in the ex vivo assays. In
contrast, c.903G>A (E8) did show dramatic alteration of splicing in the heterologous, but
not the minigene, construct experiments. Thus, the c.903G>A change is also potentially a
pathogenic mutation. Because it has also been observed in controls,11,32 it may be either a
reduced-penetrance mutation or not pathogenic.
GENOTYPE-PHENOTYPE CORRELATIONS OF GRN PATHOGENIC MUTATIONS
Detailed clinical information was available for 31 GRN mutation–positive patients from 28
different families. The mean age at onset was 57.7 years, with a wide range (39-73 years).
Clinical features of the 28 positive probands and their affected family members (3 additional
family members tested from families UP52, UPA43, and UP403) at their first examination
by a neurologist included impairments in language (21 of 26), praxis (5 of 13), and behavior
(17 of 23). Nine of 22 patients exhibited parkinsonism. The most common clinical diagnosis
was FTD (24 of 31) or subtypes of FTD including primary progressive aphasia (3 patients)
and CBS (1 patient). Three patients were initially diagnosed as having AD, whereas 1
patient carried a dual clinical diagnosis of AD and Parkinson disease. One patient had a
clinical diagnosis of dementia with Lewy bodies. In the 5 cases in which the clinical
diagnosis was not FTD or a subtype of FTD, however, the neuropathological diagnosis was
FTLD-U.
COMMENT
We screened GRN for genetic variants in 545 patients with a collection of different clinically
and/or pathologically defined neurodegenerative disorders (Table 1). Because all GRN
mutation cases reported to date, with pathological evaluation, have TDP-43 deposits, we
included disorders in which TDP-43 neuropathological findings exist for screening. We also
screened some other neurodegenerative disorders because PGRN plays a role in neuronal
stabilization,44,45 neuronal survival,46 and neurogenesis.47 The majority of cases evaluated
(434 of 545 [79.6%]) belonged to the FTD spectrum. GRN mutations that were clearly
pathogenic were identified only in FTD-spectrum cases. Pathogenic variants were scattered
throughout the entire GRN gene, consistent with the previously published spectrum of GRN
mutations.† Almost all of the pathogenic variants (≥98% in estimation) were located
between exons 1 and 11 of the GRN genomic sequence, which is basically the entire gene.
GENETIC VARIANTS AND PATHOGENICITY
The goal of the foregoing work was to identify the range of clinical and neuropathological
presentations associated with GRN mutations. Because a large number of candidate GRN
mutations were identified, to make clear the clinical-neuropathological correlations, it is
necessary to determine which genetic variants are pathogenic and which are benign with
respect to causation of neurodegenerative disease. We identified a number of variants that
are clearly pathogenic. These are either nonsense changes or variants that shift the reading
frame by insertion or deletion to produce a downstream premature stop codon. Changes
†References 9-12, 18, 20, 23-25, 29-32, 34-38.
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within the splice site acceptor and donor sequences were mostly predicted to alter splicing.
Because some of these mutations altered splice site nucleotides that are not completely
invariant (eg, c.348A>C), it was important to test each by ex vivo splicing experiments.
These experiments showed empirically that each splice site variant altered splicing and each
resulted in a frameshift and a downstream premature stop codon (eTable 2). Thus, these
mutations, listed in eTable 2, are all pathogenic. Previous work showed that premature stop
codons in GRN mRNA cause NMD. All the nonsense and frameshift mutations described in
the first section of Table 2 meet the “position of an exon-exon junction” rule for NMD.48
That is, for NMD to occur, a premature termination codon has to be located at more than 50
to 55 nucleotides upstream of the last exon-exon junction. The 3′-most premature
termination codon is generated from variant c.1414-16_1590del, and it is 100 nucleotides
upstream of the exon 11-12 junction. Therefore, we predict that all the premature
termination variants identified in this study (first section of Table 2) cause NMD and that
these mutations act by a common haploinsufficiency mechanism whereby reduced
production of the GRN gene product, PGRN, causes FTD.
For the missense variants observed, it is difficult to predict whether these changes are
pathogenic. The exception is the c.26C>A (p.A9D) change, which cosegregates with FTD in
the large hereditary dysphasic disinhibition dementia kindred.34 Shankaran et al13 further
demonstrated that this mutation prevents PGRN from being secreted. The result is
haploinsufficiency caused by failure of the mutant protein to reach its site of biological
activity. Among the other missense variants observed, one (p.R212W) was predicted by in
silico methods to have a high probability of being deleterious. However, this variant was
also observed in the controls and with a frequency similar to that in the FTD cases (Table 2);
thus, it is unlikely to be a mutation. Another 6 missense variants (p.A9D, p.R19W, p.G70S,
p.C105R, p.T182M, and p.R433W) had a moderate probability of being deleterious (eTable
3). Of these, the p.C105R variant is interesting because it alters one of the most conserved
cysteine residues in G granulin. Absence of this variant in the controls also supported the
hypothesis that this is a deleterious change. However, others reported that this variant does
not cosegregate with disease in a family with FTLD-U,11 suggesting that if it is pathogenic it
is a low-penetrance allele. Also, this change affects only 1 of the 7 granulin peptides and
thus may have only a minor effect on the total biological activity of PGRN. Interestingly, the
p.A9D (c.26C>A) variant was not predicted to be a strong candidate by the in silico
analyses, yet it is the only established pathogenic locus among the 16 missense variants.
Thus, the in silico predictions must be interpreted with caution. Additional work is needed to
examine the effects of these variants on protein localization and secretion, proteolytic
cleavage of PGRN, and granulin peptide activity.
Missense and silent variants can also affect splicing by impairing ESEs, altering exon-
splicing inhibitor sequences, or generating cryptic splice sites. In fact, many recent studies
show that silent variations can affect splicing and cause human diseases.49-51 Also, these
types of changes can alter mRNA folding, translational control, and gene regulation.52-54
We used in silico predictions and ex vivo assays to evaluate the effects of missense and
silent changes on RNA splicing. The missense variant (p.A276V, c.827C>T) and 1 of the
silent variants (c.903G>A) appear to affect splicing in at least 1 of the assays used in this
study. Thus, these changes potentially affect splicing and have the potential to produce
downstream stop codons and induce NMD.
From the results of splice site analysis and ex vivo splicing assays, we also identified 2
candidate exons (E3 and E8) that could be involved in naturally occurring alternative
splicing of GRN. According to the in silico analysis (eTable 2), the 3′ end of GRN exon 3
carries a weak splice donor site with a score of 0.26 (of a total of 1.0) in the NNSPLICE
prediction. A potential biological consequence of such a weak splice site is the presence and
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usage of alternative splice sites in the vicinity of this exon 3 donor site. In addition, our ex
vivo splicing assays with the c.1179 + 2T>C minigene construct suggested the presence of
an alternatively spliced site within exon 8 of GRN. Searching through the expressed
sequence tag database, we identified multiple GRN expressed sequence tags that were
alternatively spliced around exons 3 and 8 (Figure 2). Overall, these results suggest that
alternatively spliced isoforms of GRN could have distinct functions. Thus, some of the
missense and silent coding variants identified in this study could influence the regulation of
alternative splicing of GRN transcripts.
FREQUENCY OF PATHOGENIC GRN MUTATIONS
In this study, pathogenic mutations in GRN, all heterozygous, were detected in 30 of 434
unrelated patients (6.9%) with clinically or pathologically defined FTD (including CBS with
corticobasal degeneration, ALS/FTD, FTD with motor neuron disease, progressive
supranuclear palsy, Pick disease, and dementia lacking distinctive histopathology) and
FTLD-U. Pathogenic mutations were not detected in patients with other related diseases
(Table 1). Twenty-eight of the 30 cases identified with GRN mutations occurred in families
with a history of a similar neurodegenerative disorder, whereas 1 had insufficient history to
be definitively determined (p.C31LfsX35) and another appeared to be sporadic
(p.A472VfsX10). Overall, the frequency of GRN mutations among individuals with clinical
FTD and a family history of an FTD-like illness was 16.0% (28 of 175), and it was 6.9% (30
of 434) in all cases of clinical FTD. If only cases with autopsy-confirmed FTLD-U are
considered, the GRN mutation frequency is 56.2% (9 of 16) in individuals with a family
history and 21.4% (9 of 42) among all FTLD-U cases.
DISEASE MECHANISM CONSIDERATIONS
From this study, it is apparent that the majority of GRN mutations introduce a premature
termination codon, suggesting that their corresponding mRNAs will be degraded by the
NMD mechanism. These results support the notion that most FTD-associated GRN
mutations are expected to create functional null alleles. It also implies that normal PGRN
levels are required for neuronal survival. Although the intracellular accumulation of
pathological forms of TDP-43 is a consistent feature of FTD cases with GRN mutations,
reduction of PGRN level does not appear to induce mislocalization or generation of
pathologic TDP-43 species such as C-terminal fragments.13 Therefore, the mechanisms by
which GRN haploinsufficiency leads to neurodegeneration in FTD remains unclear. It is also
possible that other, currently unknown, molecular mechanisms account for the intrafamilial
and interfamilial clinical heterogeneity associated with GRN mutations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Neuropathological results of case ARC62 with GRN c.1414-16_1590del mutation.
Photomicrographs of middle frontal gyrus showed extensive astrogliosis of cortex and less
so of underlying white matter (A, hematoxylin-eosin, original magnification ×100; B, glial
fibrillary acidic protein, original magnification ×40), extensive tau immunoreactivity in gray
and white matter (C, tau2, original magnification ×100; gray matter above dotted line), a
cortical “tufted” astrocyte (D, tau2 immunohistochemistry, original magnification ×400),
and cytoplasmic intraneuronal inclusions that were immunoreactive for TDP-43 (E and F,
original magnification ×600) and ubiquitin (G, original magnification ×600). Similar
cytoplasmic inclusions immunoreactive for ubiquitinated TAR DNA binding protein and
ubiquitin (H, original magnification ×600) were present in the granule neurons of the dentate
gyrus of hippocampus.
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Figure 2.
GRN expressed sequence tags (ESTs) with alternatively spliced exons. The EST data were
extracted from University of California Santa Cruz genome browser (Genome
Bioinformatics Group). RefSeq indicates reference sequence.
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